An antibody-drug conjugate targeting GPR56 demonstrates efficacy in preclinical models of colorectal cancer.
Joan JacobLiezl E FranciscoTreena ChatterjeeZhengdong LiangShraddha SubramanianQingyun J LiuJulie H RoweKendra S CarmonPublished in: British journal of cancer (2023)
This study provides the rationale for the future development of a GPR56-targeted ADC approach to potentially treat a large fraction of MSS CRC patients.
Keyphrases
- end stage renal disease
- cancer therapy
- newly diagnosed
- ejection fraction
- chronic kidney disease
- fatty acid
- clinical trial
- peritoneal dialysis
- prognostic factors
- magnetic resonance imaging
- stem cells
- computed tomography
- current status
- patient reported outcomes
- magnetic resonance
- mesenchymal stem cells
- contrast enhanced